Adjuvant Therapy News and Research RSS Feed - Adjuvant Therapy News and Research

Adjuvant Therapy is treatment given after the primary treatment to increase the chances of a cure. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, or biological therapy.
New research identifies key enzyme linked to age-related increases in cancer and inflammation

New research identifies key enzyme linked to age-related increases in cancer and inflammation

For the first time, researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration, according to new research from the Perelman School of Medicine at the University of Pennsylvania. [More]
ACS, Alliance begin work on second volume of manual for cancer surgery

ACS, Alliance begin work on second volume of manual for cancer surgery

The American College of Surgeons and the Alliance for Clinical Trials in Oncology announced that they have begun work on the second volume of a comprehensive, evidence-based examination of cancer surgery techniques and recommendations. [More]
Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. [More]
Postponing chemotherapy may increase risk of death for triple-negative breast cancer patients

Postponing chemotherapy may increase risk of death for triple-negative breast cancer patients

Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center. [More]
Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%. This is the central finding of the ABCSG 18 breast cancer study regarding disease-free survival. [More]
TGen: PPF drug could help treat patients with deadly brain cancer

TGen: PPF drug could help treat patients with deadly brain cancer

In a significant breakthrough, the Translational Genomics Research Institute has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer. [More]
Study explores benefits of breast cancer adjuvant therapies

Study explores benefits of breast cancer adjuvant therapies

After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy and endocrine drugs to reduce the risk of the cancer returning. It's been assumed that the treatment effects of these therapies remain constant over time, but a new study from the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio suggests the opposite is true. [More]
Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. [More]
Caring for women who develop invasive breast tumor in Germany

Caring for women who develop invasive breast tumor in Germany

Every year, more than 70 000 women in Germany develop an invasive breast tumor. This makes breast cancer the most common tumor disease in women. The current edition of Deutsches Ă„rzteblatt International (Edition 35/36) contains no less than three articles focusing on breast cancer. [More]
EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

A recently opened double- blind phase III EORTC trial 1325 will prospectively assess whether post-operative adjuvant therapy with pembrolizumab, an anti-PD-1 monoclonal antibody, improves recurrence-free survival as compared to placebo in patients with high-risk stage III melanoma. [More]
Myriad Genetics presents two posters on myPlan Lung Cancer prognostic test at WCLC 2015

Myriad Genetics presents two posters on myPlan Lung Cancer prognostic test at WCLC 2015

Myriad Genetics, Inc. today presented two posters on its myPlan Lung Cancer prognostic test at the International Association for the Study of Lung Cancer 16th World Conference on Lung Cancer being held in Denver, Colo. [More]
New study reveals conflicting role of two subtypes of pancreatic cancer stroma

New study reveals conflicting role of two subtypes of pancreatic cancer stroma

Dense surrounding tissue can block drugs from reaching pancreatic cancer tumors, but it can also help prevent the cancer from spreading. Now a new study by UNC Lineberger Comprehensive Cancer Center researchers and collaborators helps explain the conflicting role of the surrounding tissue known as stroma. In the study, the researchers revealed that based on molecular characteristics, there are two subtypes of pancreatic cancer stroma. [More]
Beta-blockers improve overall survival among epithelial ovarian cancer patients

Beta-blockers improve overall survival among epithelial ovarian cancer patients

In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. [More]
WBRT associated with worse cognitive function than radiosurgery, shows study

WBRT associated with worse cognitive function than radiosurgery, shows study

Whole Brain Radiation Therapy (WBRT) is associated with significantly worse cognitive function than radiosurgery, and should no longer be used in the adjuvant setting after radiosurgery to treat cancer patients with brain metastases, according to a large study led by a researcher at The University of Texas MD Anderson Cancer Center. [More]
Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Heather Wakelee, MD, is the recipient of the 2015 ECOG-ACRIN Young Investigator Award, the ECOG-ACRIN Cancer Research Group announced today. Dr. Wakelee is associate professor of medicine in the Division of Oncology at the Stanford University School of Medicine in Stanford, Calif. [More]
Vitamin D3 and metformin show promising results in preventing colorectal cancer

Vitamin D3 and metformin show promising results in preventing colorectal cancer

The concept was simple: If two compounds each individually show promise in preventing colon cancer, surely it's worth trying the two together to see if even greater impact is possible. [More]
Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

Important news for men receiving treatment for prostate cancer: Two new studies from the University of Virginia School of Medicine have upended the widely held view that it's best to delay radiation treatment as long as possible after the removal of the prostate in order to prevent unwanted side effects. [More]
New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

A new study finds that the use of adjuvant systemic therapy for localized gastrointestinal stromal tumors (GISTs ) has significantly increased over time and that patients treated with the therapy have better survival than those treated with surgery alone. [More]
Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). [More]
20th annual edition of NCCN Guidelines for Breast Cancer published

20th annual edition of NCCN Guidelines for Breast Cancer published

Breast cancer is the most frequently diagnosed cancer globally and the leading cause of cancer-related death in women. However, the incidence of breast cancer has somewhat stabilized over the past few decades, and breast cancer mortality appears to be declining, suggesting a benefit from the combination of early detection and more effective treatment. [More]
Advertisement
Advertisement